Under-the-radar San Diego startup Hera Therapeutics looks to be raising some early-stage capital to further its work in the antivirals space.
The company, which is developing direct acting antivirals for human papilloma virus, human and animal retroviruses and herpes group viruses, filed regulatory paperwork to raise $1.3 million. It has thus far raised $1.1 million in the form of debt, according to the filing. Calls to the company to determine the use of this latest financing round were unanswered.
Hera also raised $1.1 million in equity financing last year, according to another filing.
Tackling Rising Drug Costs and Growing Popularity of GLP-1’s
See how Quantum Health is providing the steps to help their members tackle the cost of specialty medications and other drugs.
Hera Therapeutics is housed in the Janssen Labs accelerator in San Diego. It was founded in late 2012 by Karl Hostetler, a professor emeritus at University of California, San Diego whose lab has focused on developing antivirals for a number of infectious diseases including herpes simplex, hepatitis B and C, HIV-1, Epstein Barr virus and a number of poxes.
[Image of herpes sign from Flickr user Alexander Rutz]